EULAR Highlights 2017

Enhancing knowledge of the clinical
importance of cytokine signalling
The Cytokine Signalling Forum
www.cytokinesignalling.com
EULAR 2017
Conference Highlights
Register for all this FREE content at
www.cytokinesignalling.com
www.cytokinesignalling.com
info@cytokinesignalling.com
@CytokineForum
lnkd.in/PyqQPm
Supported by an unrestricted educational grant
from Pfizer Italia S.R.L., Lilly and R-Pharm.
Developed under the auspices of the University of Glasgow

Chairman’s Welcome
Dear CSF Member,
Thank you for your continued support of the Cytokine Signalling Forum. We are now in our fourth year, and continue to strive to bring you the most
up-to-date and interesting data in cytokine signalling. To that end, I am delighted to share with you our pick of the EULAR highlights for 2017.
We have identified the most interesting and impactful abstracts being presented at this year’s meeting on both cytokine signalling and IL-6.
I have also selected my ‘Chairman’s picks’: those abstracts that I feel are the most significant at this year’s congress.
Cytokine Signalling
Again, this year there is an interesting range of both basic and clinical science. There are several baricitinib posters covering durability and
maintenance of efficacy [FRI0096], switching to monotherapy [SAT0058], and dose reduction [SAT0072]. The possibility of an anti-inflammatory
biomarker profile in patients treated with filgotinib monotherapy is examined [THU0182], and the results of the DARWIN-3 open label extension study
up to 144 weeks are presented in Thursday’s poster session and tour [THU0173].
Tofacitinib posters in RA concentrate on long-term safety and efficacy over eight years [THU0197] as well as an examination of cardiovascular risk
factors [SAT0686], and safety and efficacy in patients with an inadequate response to conventional synthetic or biologic DMARDs [THU0185].
Real-world tofacitinib drug-retention data are also shared as a poster from the Swiss SCQM registry [THU0174]; and real-world tofacitinib
monotherapy data from the US CORRONA registry as an oral presentation [OP0022]. Three further oral presentations on Thursday and Friday will
share exciting new data from the Phase 3 tofacitinib studies in psoriatic arthritis [OP0202; OP0216] as well as long-term effectiveness of live zoster
vaccine in patients with RA, subsequently treated with tofacitinib [OP0230].
IL-6
Several abstracts showcase key data from the clinical programmes of sarilumab, sirukumab and tocilizumab.
There are three key presentations on sarilumab, including patient-reported (PROs) from two Phase 3 studies in RA [FRI0240], and efficacy and
patient-reported benefits of sarilumab monotherapy versus adalimumab monotherapy in the MONARCH study [SAT0202; OP0102].
Sirukimab posters focus on Phase 3 data in RA, with efficacy and safety from the SIRROUND-T study [FRI0214], analyses of health-related quality
of life and work productivity from SIRROUND-D and -T, respectively [FRI0246; FRI0251], and an integrated safety analysis of the SIRROUND
programme [SAT0194].
Tocilizumab oral presentations examine tapering and dose reduction strategies [OP0104] as well as the long-term safety profile seen in clinical trials
and post-marketing populations [OP0105]. Tocilizumab posters look at real-world data, with clinical remission in the TOSPACE trial [SAT0183], and a
pooled analysis of Phase 4 data across 22 countries [SAT0199].
The following pages provide an overview of these topics and highlight my ‘Chairman’s picks’. Once again, thank you for your support and
enjoy EULAR 2017!
Yours,
Prof. Iain McInnes

Key Presentations – Cytokine Signalling
Wednesday, June 14, 2017
ORAL PRESENTATIONS
Still breaking news on TNF inhibitors in
Rheumatoid Arthritis
Hall 8 – 17:00-18:30
OP0022
TNFi and Tofacitinib Monotherapy and Comparative Effectiveness in
Clinical Practice: Results from CORRONA Registry
Thursday, June 15, 2017
ORAL PRESENTATIONS
Advances in RA and SpA pathophysiology
N111/N112 – 10:15-11:45
OP0161
Thursday, June 15, 2017
POSTERS
THU0078
THU0081
THU0088
THU0114
THU0148
THU0173
THU0174
THU0175
The JAK1 Selective Inhibitor Filgotinib Regulates Both Enthesis and
Colon Inflammation in a Mouse Model of Psoriatic Arthritis
PsA: an integrated perspective
Hall 8 – 15:30-17:00
OP0202
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in
Patients With Active Psoriatic Arthritis and an Inadequate Response to
Tumour Necrosis Factor Inhibitors: Opal Beyond, A Randomised,
Double-Blind, Placebo-Controlled, Phase 3 Trial
Concomitant Use of Conventional Synthetic DMARDs and Response
to Baricitinib
Differences in Patient-Reported Outcomes Between Baricitinib and
Comparators Among Patients With Rheumatoid Arthritis who Achieved
Low Disease Activity or Remission
Structural Damage Progression in Patients Treated With Methotrexate,
Baricitinib Monotherapy or Baricitinib + Methotrexate Based on Their
Level of Clinical Response in the Phase 3 RA-BEGIN Study
Effects of Smoking on Baricitinib Efficacy in Patients With Rheumatoid
Arthritis: Pooled Analysis From Two Phase 3 Clinical Trials
Increase of Night QT-Interval Duration in Rheumatoid Arthritis Patients
Treated With Tofacitinib During 12-Month Follow-Up
Long Term Safety and Efficacy of Filgotinib in a Phase 2b Open Label
Extension Study in Patients With Rheumatoid Arthritis: Results up to 144
Weeks
Drug Retention of Tofacitinib Versus Biologic Antirheumatic Agents in
Rheumatoid Arthritis: Observational Data from the Swiss SCQM Registry
Inflammation Detected With Modern Sensitive MRI Analysis Demonstrates
That Therapeutic Response as Early as One Month Predicts 12-Month
Radiographic Progression: Data From a Study Using Tofacitinib and
Methotrexate in Methotrexate-Naïve Patients With Early RA
THU0177
THU0182
THU0185
THU0186
THU0188
THU0189
THU0191
THU0193
THU0195
THU0196
THU0197
THU0199
THU0205
THU0206
THU0210
THU0211
THU0213
THU0215
THU0352
ABT-494 Pharmacokinetics Following Administration of the Once-Daily
Extended-Release Tablet Formulation Being Utilized in the Ongoing
Rheumatoid Arthritis Phase 3 Trials
Monotherapy with the JAK1-Selective Inhibitor Filgotinib Displays an
Anti-Inflammatory Biomarker Profile in Rheumatoid Arthritis Patients
Comparison of Tofacitinib Safety and Efficacy in Rheumatoid Arthritis
Patients With Inadequate Response to Conventional Synthetic DMARDs,
or to One or More Biological DMARDs
Magnitude and Duration of Early Response With Tofacitinib: Post-Hoc
Analysis of Two Phase 3, Placebo-Controlled Studies
Efficacy and Safety of Tofacitinib in Patients With Rheumatoid Arthritis
Who Did Not Respond to Synthetic and Biological DMARDs in
Clinical Practice
Safety of Four Treatment Regimens in Early Rheumatoid Arthritis
Effects of Tofacitinib, an Oral Janus Kinase Inhibitor, on Patient-Reported
Outcomes in Japanese Patients With Rheumatoid Arthritis
Reestablishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor,
in Rheumatoid Arthritis Patients After Temporary Discontinuation
Consistent Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis
Patients With Inadequate Response or Intolerance to Non-MTX
csDMARDs
Systematic Review and Meta-Analysis of Malignancies, Excluding Non-
Melanoma Skin Cancer, in Patients With Rheumatoid Arthritis Treated
With Tofacitinib or Biologic Disease-Modifying Antirheumatic Drugs
Tofacitinib, an Oral Janus Kinase Inhibitor, in The Treatment of
Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term
Extension Studies Over 8 Years
Tofacitinib Improves Left Ventricular Mass and Cardiac Output in
Patients With Rheumatoid Arthritis
Effects of the JAK1-Selective Inhibitor Filgotinib on Multibiomarker
Disease Activity Scores in Patients With Active Rheumatoid Arthritis and
an Inadequate Response to Methotrexate
The JAK1-Selective Inhibitor Filgotinib Reduces Multiple Markers of
Inflammation Linked to Various Pathologic Cell Types and Processes in
Rheumatoid Arthritis Patients
Changes in Hemoglobin Levels Upon Treatment With ABT-494, A
Selective JAK-1 Inhibitor, and Relation to Baseline Levels of
C-Reactive Protein
Meta-Analysis of Serious Infections With Baricitinib, Tofacitinib and
Biologic DMARDs in Rheumatoid Arthritis
Comparative Efficacy and Safety of Baricitinib 2 Mg and 4 Mg in
Patients With Active Rheumatoid Arthritis: A Bayesian Network Meta-
Analysis of Randomized Controlled Trials
Effects of Tofacitinib on Patient-Reported Outcomes in a Phase 3 Study
of Chinese Patients With Active Rheumatoid Arthritis and an Inadequate
Response to DMARDs
Tofacitinib Treatment is Associated With Attainment of the Minimally
Important Reduction in Axial MRI Inflammation in Patients With
Ankylosing Spondylitis
Chairman’s picks

Friday, June 16, 2017
ORAL PRESENTATIONS
From classics to new: synthetic DMARDs in RA
Hall 7A – 10:15-11:45
LB0003
OP0230
Tofacitinib With and Without Methotrexate Versus Adalimumab With
Methotrexate for the Treatment of Rheumatoid Arthritis: Results From
Oral Strategy, A Phase 3b/4 Randomised Trial
The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated
With Tofacitinib
PsA: the options grow!
Hall 8 – 10:15-11:45
OP0216
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or
Adalimumab in Patients With Active Psoriatic Arthritis and an Inadequate
Response to Conventional Synthetic Disease-Modifying Antirheumatic
Drugs (csDMARDs): A Randomised, Placebo-Controlled, Phase 3 Trial
Friday, June 16, 2017
POSTERS
FRI0071
FRI0086
Tofacitinib Restores the Inhibition of Reverse Cholesterol Transport
Induced by Inflammation: Understanding the Lipid Paradox Associated
With Rheumatoid Arthritis
Efficacy and Safety Data Based on Historical or Pre-Existing Conditions
at Baseline for Patients With Active Rheumatoid Arthritis Who Were
Treated With Baricitinib
FRI0087 Low Rates of Radiographic Progression of Structural Joint Damage Over 2
Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis
FRI0089 Effect of Starting Dose of Baricitinib In Achieving Sustained Low
Disease Activity
FRI0090 Analysis of Neutrophils, Lymphocytes, and Platelets In Pooled Phase 2
and Phase 3 Studies of Baricitinib for Rheumatoid Arthritis
FRI0092 Effects of Baricitinib on Haemoglobin and Related Laboratory
Parameters in Rheumatoid Arthritis Patients
FRI0096 Durability and Maintenance of Efficacy Following Prolonged Treatment
With Baricitinib
FRI0124 Temporary Interruptions of Study Drug During the Baricitinib Phase 3
Rheumatoid Arthritis Program
FRI0231 The First Report of Significant Increase of Body Mass Index in
Rheumatoid Arthritis Patients Treated With Tofacitinib During 12-Month
Follow-Up
FRI0428 The JAK1-Selective Inhibitor, Filgotinib, Inhibits Inflammation Pathways
Observed in an IL23-Induced Psoriatic Arthritis Mouse Model
FRI0496 Comparing Tofacitinib Safety Profile in Patients With Psoriatic Arthritis in
Clinical Studies With Real-World Data
FRI0509 Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up To
24 Months in Patients With Active Psoriatic Arthritis: Interim Data From
Opal Balance, an Open-Label, Long-Term Extension Study
Saturday, June 17, 2017
POSTERS
SAT0055
SAT0058
SAT0069
SAT0070
SAT0072
SAT0149
SAT0217
SAT0439
SAT0469
SAT0686
EULAR 2017
Baricitinib Showed Rapid and Greater Reduction in Pain Compared to
Adalimumab or Placebo in Patients With Rheumatoid Arthritis
Effects of Baricitinib on Patients Who Stop Methotrexate Monotherapy
and Switch to Baricitinib Monotherapy
A Rapid3-Like Index Documents Superior Efficacy of Baricitinib to
Adalimumab and Placebo, Similar To DAS28 And CDAI In The Ra-Beam
Clinical Trial In Patients With Rheumatoid Arthritis
Baricitinib Versus Adalimumab in Patients With Active Rheumatoid Arthritis:
Analysis Of Patients Achieving a Moderate EULAR Response at Week 4
Dose Reduction of Baricitinib in Patients With Rheumatoid Arthritis
Achieving Sustained Disease Control: Results of a Prospective Study
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional
Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Early Patient-Reported Outcomes and Clinical Outcomes With ABT-494
in Patients With Active Rheumatoid Arthritis Who Are Inadequate
Responders to Methotrexate or Tumor Necrosis Factor Inhibitors: Post-
Hoc Analysis Of Phase 2 Randomized Controlled Trials
Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor,
in Patients With Active Psoriatic Arthritis
Major Adverse Cardiovascular Events: Risk Factors in Patients With RA
Treated With Tofacitinib
ABSTRACT ONLY
AB0098 Effects of Tofacitinib in Early Arthritis Bone Loss
AB0235 Effect of Baseline Disease Activity on Achieving Sustained Low Disease
Activity in Baricitinib Phase 3 Studies
AB0261 Clinical and Structural Responses of Patients With Active Rheumatoid
Arthritis (RA) Using Step-Up Dosages of Tofacitinib In A Treat To
Target Approach
AB0281 Characterization of Changes In Lymphocyte Subsets in Baricitinib-
Treated Patients With Early, DMARD Naïve, Rheumatoid Arthritis In A
Phase 3 Study
AB0403 Adherence and Access to Biological Therapy and Tofacitinib in a Cohort
of Colombian Patients With Rheumatological Diseases
AB0407 Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy With
Tumor Necrosis Factor Inhibitors (TNFi) in Combination With Varying
Doses of Methotrexate (MTX) in Patients With Rheumatoid Arthritis
AB0419 Real World Use of Tofacitinib in Rheumatoid Arthritis: Data From
Latin America
AB0431 Post-Marketing Surveillance of Tofacitinib in Japanese Patients With
Rheumatoid Arthritis: An Interim Report Of Safety Data
AB0432 ABT-494 Has No Effect on the QT Interval at the Doses Being Evaluated
in Rheumatoid Arthritis Phase 3 Trials
AB0434 Tofacitinib in Rheumatoid Arthritis: Real Life Experience
AB0436 Comparison of Tofacitinib Efficacy in Patients With Moderate vs Severe
Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies
AB0794 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With
Active Psoriatic Arthritis: Results from Two Phase 3 Studies
Chairman’s picks

Key Presentations – IL-6
Thursday, June 15, 2017
ORAL PRESENTATIONS
Progress in biological treatment of RA
Hall 8 – 10:15-11:45
OP0102
OP0103
OP0104
OP0105
Patient Reported Benefits of Sarilumab Monotherapy Versus Adalimumab
Monotherapy in Adult Patients with Active Rheumatoid Arthritis
The Effect of Sirukumab Plus Methotrexate on Circulating Biomarkers
of Joint Destruction in Moderate to Severe Rheumatoid Arthritis Patients
from the SIRROUND-D Phase 3 Study
Tocilizumab: Dose Reduction or Interval Spacing – Which Proves a
Better Tapering Strategy for Rheumatoid Arthritis in Clinical Remission?
Long-Term Safety of Tocilizumab from Large Clinical Trial and
Postmarketing Populations
Heterogeneity in JIA
N105/N106 – 13:30-15:00
OP0197
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than
Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Thursday, June 15, 2017
POSTERS
THU0055
THU0130
THU0134
THU0503
THU0511
THU0526
THU0567
Low Molecular Weight BAFF Signaling Inhibitors Ameliorate IL-6, IL-10
and IgG Production In Vitro and In Vivo Models of Autoimmune Diseases
Improvement in Measures Of Depressed Mood And Anhedonia in Two
Randomized, Placebo-Controlled Phase III Studies Of Sirukumab, A
Human Anti-Interleukin-6 Antibody, in Patients With Rheumatoid Arthritis
Interstitial Lung Disease and Rheumatoid Arthritis. Multicenter Study
With Tocilizumab
Identification of Optimal Subcutaneous (SC) Doses of Tocilizumab in
Children With Polyarticular-Course Juvenile Idiopathic Arthritis (PCJIA)
Tocilizumab is a Promising Treatment Option for Therapy Resistent
Juvenile Localised Scleroderma Patients
Short and Long-Term Follow-Up of Tocilizumab for Severe Juvenile
Idiopathic Arthritis-Associated Uveitis
Rapid Improvement with Tocilizumab in Refractory and Severe Uveitic
Cystoid Macular Edema
THU0577 Tocilizumab Monotherapy for Adult Onset Still’s Disease ~ Results of 52-
Week Treatment of a Prospective, Single-Center, Single-Arm, Open Trial
Friday, June 16, 2017
POSTERS
FRI0213
FRI0214
FRI0215
FRI0225
FRI0227
FRI0228
FRI0233
FRI0239
FRI0240
FRI0242
FRI0243
FRI0246
FRI0247
FRI0248
FRI0251
Comparative Effectiveness of Abatacept, Rituximab, Tocilizumab and
Anti-TNF Biological DMARDs In RA: Results from the Nationwide
Swedish Register
Long-Term Efficacy and Safety of Sirukumab in Patients with Active
Rheumatoid Arthritis Despite Anti-Tumor Necrosis Factor Therapy:
Results of the Randomized, Phase 3 SIRROUND-T Study
Comparative Efficacy and Retention Rate of Tocilizumab and TNF Inhibitors
used in Combination With Methotrexate as First-Line Biologic Therapy in
Rheumatoid Arthritis: Data from a Multicentre Observational Registry
Anemia is a Better Predictor for Radiographic Damage in Rheumatoid
Arthritis Than DAS28 When Determined Before Start of Tocilizumab-
Treatment – A Secondary Analysis From The ACT-Ray Trial
Sarilumab Significantly Suppresses Circulating Biomarkers of Bone
Resorption and Cardiovascular Risk Compared With Adalimumab:
Biomarker Analysis from the Phase 3 Monarch Study
UGT1A1 Genetic Variants Are Associated With Increases In Bilirubin
Levels In Rheumatoid Arthritis Patients Treated With Sarilumab
The Retention Rates of Abatacept in Elderly RA Patients (65 Years and
Above) Who Cannot Be Treated With Methotrexate: Comparison With
Etanercept And Tocilizumab; A Single-Center, Retrospective, Case-
Control Study
Results of a Phase 2b Study of Vobarilizumab, an Anti-Interleukin-6
Receptor Nanobody, as Monotherapy In Patients With Moderate To
Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA) Impact Following Treatment With Sarilumab:
Patient Reported Outcomes Using The Raid Scale From Two
Randomized Phase III Trials
Association Between Clinical and Radiographic Responses, and Physical
Function in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients
with Active, Moderate-To-Severe Rheumatoid Arthritis
Sirukumab Treatment Reduces Levels of Iron-Regulatory Proteins and
Ameliorates Inflammation-Associated Anemia in Rheumatoid Arthritis
Patients
Improvements in Health-Related Quality of Life With Sirukumab are
Statistically Significant, Clinically Meaningful, and Meet or Exceed
Normative Values in Rheumatoid Arthritis Patients with Inadequate
Response to Disease-Modifying Antirheumatic Drugs: Post Hoc Analyses
of a Phase 3 Trial
Median Time to Low Disease Activity is Shorter in Tocilizumab
Combination Therapy With csDMARDs as Compared to Monotherapy in
Patients with Active Rheumatoid Arthritis and Inadequate Responses to
csDMARDs and/or TNF Inhibitors: Subanalysis of the Swiss and Austrian
Patients from The ACT-Sure Study
Incidence Of Melanoma In Patients With Rheumatoid Arthritis Treated
With Tocilizumab
Sirukumab, an Anti-Il-6 Cytokine Monoclonal Antibody, Leads to
Improvements in Work Productivity and General Health Status in
Patients with Active Rheumatoid Arthritis Refractory to Anti-TNF
Therapy: Results from the Phase 3 SIRROUND-T Study
Chairman’s picks

FRI0252
FRI0253
FRI0254
FRI0313
FRI0321
FRI0336
FRI0673
Saturday June 17, 2016
POSTERS
SAT0026
SAT0083
SAT0170
SAT0181
SAT0182
SAT0183
SAT0184
SAT0189
SAT0192
SAT0193
SAT0194
Summary of Neutropenia in Patients with Rheumatoid Arthritis Treated
with Sirukumab in the SIRROUND Phase 3 Clinical Trials
Patient-Reported Outcomes in Patients with Rheumatoid Arthritis
Treated with Subcutaneous Tocilizumab Compared with Placebo or
Intravenous Tocilizumab in Combination with csDMARDs
Efficacy of Tocilizumab for Suppressing Radiographic Progression of
Cervical Lesions in Patients with Rheumatoid Arthritis Comparison
with Methotrexate Treatment; Two Years of Follow-Up ~A Multicenter
Registry Study ~
The Efficacy and Safety of Tocilizumab Therapy in Patients With
Polymyalgia Rheumatica who were Resistant or Intolerant to
Glucocorticoids and Additional Methotrexate
Circulating Il-6 and Other Metabolic Biomarkers Comparing Effects
of Modified-Release Prednisone (MR) and Immediate-Release
Prednisolone (IR) in new GCA
Efficacy of Tocilizumab in 31 Patients with Giant Cell Arteritis
Clinical Remission in Tocilizumab-Using Rheumatoid Arthritis Patients
can be Overestimated: A Cross Sectional Study Using Ultrasound
Sonography
Signalling Through Insulin-Like Growth Factor 1 Receptor Contributes
to IL-6 Production and Supports T Cell Dependent Inflammation in
Rheumatoid Arthritis
Tocilizumab Induced Clinical Remission in Rheumatoid Arthritis had
More Residual Doppler Signals in Comparison With Other Biologics
B-Cell Phenotype and IGD-CD27- Memory B Cells are Affected by TNF-
Inhibitors and Tocilizumab Treatment in Rheumatoid Arthritis
Low Dose Interleukin-2 Combined with Tocilizumab Selectively
Increases Regulatory T Cells Helping Refractory Rheumatoid Arthritis
Patients Achieve Remission More Rapidly
Sirukumab Leads to Significant and Clinically Meaningful Improvements
in Health-Related Quality of Life That Meet or Exceed Normative Values
in Patients With Rheumatoid Arthritis Refractory to TNF Inhibitors in Post
Hoc Analyses of a Phase 3 Trial
Clinical Remission in Subjects With Rheumatoid Arthritis Treated With
Subcutaneous Tocilizumab as Monotherapy or in Combination With
Methotrexate Or Other Synthetic Dmards: A Real-World Clinical Trial
(TOSPACE)
Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients With
Reduced Doses of Intravenous Tocilizumab
Factors Influencing the Prescription of Tocilizumab Alone or in
Combination With DMARDs in Rheumatoid Arthritis Patients in a Real
Life Setting. Pooled Analysis of 3 Observational Studies
Sarilumab Suppresses Thrombosis-Related Gene Expression in
Circulating Blood Cells in MTX-IR and TNF-IR Patients With Active
Rheumatoid Arthritis
RA Patients With Inflammatory Anemia Benefit From Increased
Hemoglobin and Decreased Fatigue Under Tocilizumab Therapy
Sirukumab Integrated Safety in Rheumatoid Arthritis Patients: Analysis
of the SIRROUND Phase 3 Data
SAT0198 Tocilizumab for the Management of Rheumatoid Arthritis:
Discontinuation Due to Inefficacy and Toxicity – Experience from a Large
Teaching Hospital
SAT0199 Subcutaneous Tocilizumab Monotherapy or Combined With a csDMARD
in Patients With Rheumatoid Arthritis: Tozura, a Pooled Analysis of Phase
IV Studies In 22 Countries
SAT0202 Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab
Monotherapy in Patients With Active Rheumatoid Arthritis in the Phase 3
Monarch Study, Including Subpopulations
SAT0203 Significance of Extension of Tocilizumab Infusion Intervals From 4
Weeks to 6 Weeks in RA Patients Who Had Shown Good Response to 4
Week Intervals
SAT0206 Retention of Tocilizumab as Monotherapy Versus TNF Inhibitors With
Conventional Synthetic DMARDs in Rheumatoid Arthritis Patients With
Inadequate Response to TNF Inhibitors: A Study From The TOCERRA
Collaboration
SAT0209 Observational Study on the Effects of IL-6 Inhibitor Therapy on Myostatin
in Patients With Rheumatoid Arthritis
SAT0212 Sarilumab Dose Reduction in an Open-Label Extension Study in RA
Patients With Inadequate Response to TNF Inhibitors
SAT0214 An Analysis of Increasing Spacing Time for the Intravenous
Administration of Tocilizumab in Patients With Rheumatoid Arthritis
SAT0218 Effect of Tocilizumab in DMARD-Naïve Early Rheumatoid Arthritis Patients
on Health-Related Quality Of Life: Results of the U-ACT-Early Trial
SAT0524 Utility of Tocilizumab in Clinical Manifestations of Erosive Osteoarthrosis
of Hands
Regional Hospital ISSTE Puebla, México
Chairman’s picks

EULAR 2017
ABSTRACT ONLY
AB0051 Interleukin-6 Blockade With Tocilizumab Decreases Metalloproteinase-9
Activity in Synovial Fibroblasts Stimulated With Synovial Fluids of
Patients With Rheumatoid Arthritis or Spondyloarthritis
AB0238 The Influence of Fatigue in the Definition of Remission in Rheumatoid
Arthritis Patients Treated With Tocilizumab
AB0395 Subcutaneous Tocilizumab as Monotherapy or in Combination With a
csDMARD In Patients With Rheumatoid Arthritis: 24 Weeks Results Of
The French Phase IIIb Study, “Tosca”
AB0396 Tocilizumab I.V. Effectiveness in RA Patients is Independent of
Smoking Status
AB0400 Efficacy and Safety of Intravenous and Subcutaneous Tocilizumab in a
Cohort of Patients Affected by Rheumatoid Arthritis in Real-Life
AB0401 The Efficent Regulation of Tocilizumab for the Expression Of CD4+/
CD8+ T/CD19 + B Cells and the Immunoglobulin in Systemic Juvenile
Idiopathic Arthritis
AB0406 Stable Efficacy and Safety After Switching From Tocilizumab Intravenous
to Subcutaneous in Rheumatoid Arthritis: Results of a Cohort of
200 Patients
AB0407 Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy With
Tumor Necrosis Factor Inhibitors (TNFi) in Combination With Varying
Doses of Methotrexate (MTX) in Patients With Rheumatoid Arthritis
AB0409 Corticosteroid-Sparing in Patients With Rheumatoid Arthritis on
Tocilizumab: First Experience Of Bab -El- Oued Hospital
AB0413 Induction and Progression of Subcutaneous Nodulosis in Rheumatoid
Arthritis Patients Treated With Tocilizumab
AB0416 Which Factors Predict the Responsiveness to Tocilizumab in Rheumatoid
Arthritis? The Difference Between the Usage as the First Biologic and as
the Second Biologic
AB0952 Experience of Tocilizumab Use in Treatment of Juvenile Idiopathic
Atrtritis in Chelyabinsk Regional Children Hospital
AB0964 Some Pecularities of the Course of Juvenile Idiopathic Arthritis in
Patients Treated With Tocilizumab
AB0984 Tocilizumab Monotherapy for Polymyalgia Rheumatica ~ Results of 52-
Week Treatment of a Prospective, Single-Center, Open, Single-Arm Trial

Register for all this FREE content at
www.cytokinesignalling.com
www.cytokinesignalling.com
info@cytokinesignalling.com
@CytokineForum
lnkd.in/PyqQPm
Supported by an unrestricted educational grant
from Pfizer Italia S.R.L., Lilly and R-Pharm.
Developed under the auspices of the University of Glasgow